Medical Data Analysis of CYP1B1 Gene Polymorphism and Clinical Prognosis of Minimally Invasive Surgery for Lung Cancer.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2022
2022
Historique:
received:
07
07
2022
revised:
27
07
2022
accepted:
25
08
2022
entrez:
4
10
2022
pubmed:
5
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
To address the issue of genetic mutations in medical records, clinical studies on minimally invasive surgery for breast cancer have been proposed. The CYP1B1 gene is mainly a single-nucleotide mutation, which affects the enzymatic reaction related to carcinogens and causes the susceptibility differences of different individuals. First, the survival rate and other factors influencing the estimation of 120 leukemia patients were examined with the help of various medical records by establishing an organization for auxiliary diagnosis of lung cancer based on expertise. Secondly, through the treatment of 120 leukemia patients after minor surgery, the average life expectancy of 120 patients was 19 months, the one-year survival rate was 74.61%, and the two-year survival rate was 32.70%. Currently, there are more than 160 cases of CYP1B1 discovered. In recent years, people have gradually entered into in-depth research on the correlation between genes and lung cancer, which is of great significance to the treatment and research of lung cancer. An analysis showed patients' age, stage, whether they would work, whether radiation therapy and antibiotics were offered, and so on. s has a direct impact on patient survival, and many tests have shown that the patient's age, stage, whether it will work, and whether fire radiation and drug therapy are provided are important interventions for patients with anemia. Finally, in patients with leukemia, especially during the restricted period, combined treatment with a physician, radiologist, and surgeon should be initiated as soon as possible. For a wide range of disease, depending on the use of chemotherapy, local metastasis with antibiotics can improve the disease. After success, it is more beneficial to choose second-line treatment.
Identifiants
pubmed: 36193313
doi: 10.1155/2022/5217625
pmc: PMC9526583
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carcinogens
0
Nucleotides
0
CYP1B1 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP1B1
EC 1.14.14.1
Types de publication
Journal Article
Retracted Publication
Langues
eng
Sous-ensembles de citation
IM
Pagination
5217625Commentaires et corrections
Type : RetractionIn
Informations de copyright
Copyright © 2022 Xia Han et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest regarding the publication of this article.
Références
Curr Opin Pulm Med. 2004 Jul;10(4):261-5
pubmed: 15220749
Vopr Onkol. 2015;61(3):413-7
pubmed: 26242154
Curr Treat Options Oncol. 2020 Aug 7;21(10):80
pubmed: 32767154
Clin Chest Med. 2020 Jun;41(2):175-183
pubmed: 32402354
Thorac Surg Clin. 2009 Aug;19(3):345-51
pubmed: 20066946
Indian J Cancer. 2015 Feb;51 Suppl 2:e2
pubmed: 25712835
Digestion. 2018;97(1):13-19
pubmed: 29393164
Oncologist. 2007 Oct;12(10):1205-14
pubmed: 17962614
J Minim Invasive Gynecol. 2011 Nov-Dec;18(6):820-2
pubmed: 22024271
Magy Onkol. 2020 Sep 23;64(3):190-195
pubmed: 32966349
Ann Thorac Cardiovasc Surg. 2009 Apr;15(2):71-3
pubmed: 19471218
Semin Thorac Cardiovasc Surg. 2014 Spring;26(1):36-43
pubmed: 24952756
Gastrointest Cancer Res. 2008 Nov;2(6):283-6
pubmed: 19259276
Kaohsiung J Med Sci. 2017 Mar;33(3):124-129
pubmed: 28254114
Semin Thorac Cardiovasc Surg. 2007 Winter;19(4):311-8
pubmed: 18395630
Kyobu Geka. 2019 Jan;72(1):51-56
pubmed: 30765629
Cancer J. 2011 Jan-Feb;17(1):18-22
pubmed: 21263262
Gen Thorac Cardiovasc Surg. 2020 Dec;68(12):1517-1522
pubmed: 31828519
Chest. 1995 Jun;107(6 Suppl):298S-301S
pubmed: 7781410